echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Tianyan Pharmaceuticals to Present Four Posters at the American Cancer Society (AACR) Annual Meeting Showcasing Strong Data on the Company's Transformative Preclinical Product Pipeline

    Tianyan Pharmaceuticals to Present Four Posters at the American Cancer Society (AACR) Annual Meeting Showcasing Strong Data on the Company's Transformative Preclinical Product Pipeline

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    -POWERbody® powerful antibody integrates SAFEbody® precision masking technology, designed to greatly improve efficacy on the basis of ensuring drug safety

    - Data demonstrate that safe, robust and durable immunotherapy targeting solid tumors can be achieved by covering and combining different mechanisms of action and pathways in the cancer immune cycle

    Suzhou, China and San Diego, U.


    In the poster session, Zhongtianyan will present the preclinical data of the company's three highly differentiated, potentially best-in-class, IND-enabling drug candidates (ADG138, ADG206 and ADG153), as well as the company's tailored dual drug candidates.


    Details of the poster presentation include:

    • Abstract Title: ADG138, a Novel HER2×CD3 POWERbody? Potent Antibody Combining Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and Off-target Toxicity of Monotherapy and Combination Therapy in HER2-expressing Solid Tumors


      Dr.


      About Tianyan Pharmaceutical

      Tianyan Pharmaceutical (Nasdaq: ADAG) is a platform-driven clinical product development stage biopharmaceutical company with independent platform outputs.


      For more information, please visit: https://investor.


      SAFEbody ® is a registered trademark of Tianyan in the United States, China, Australia, Japan, Singapore and the European Union


      Safe Harbor Statement

      This press release contains forward-looking statements, including statements regarding preclinical studies of ADG138, ADG206, ADG153G-1 and bispecific potent antibodies targeting CD28, the potential impact of the results of the preclinical studies of these antibodies, and the advancement of Tianyan Pharmaceuticals and anticipated clinical development, regulatory milestones, and commercialization of Tianyan's pipeline product candidates


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.